Pravafen

Phase 3Small molecule

Shionogi

Pravafen is one of 9 small molecule programs targeting Combined hyperlipidemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Combined HyperlipidemiaActive, not recruiting

Combined HyperlipidemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Combined Hyperlipidemia

#DrugCompanyPhaseTrials

Niacor

Zocor

Repatha

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 5

Tricor

JJagotec

Phase 3

1 6

Lipid Modification

YYonsei University

Approved

1 7

Berberine

XXijing Hospital of Digestive Diseases

Pravafen

1 9

Zetia

OOrganon and Co

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Combined hyperlipidemia1 trial

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Completed· Shionogi logo

Shionogi·Phase 3·NCT00459745·481 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pravafen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pravafen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pravafen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shionogi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Shionogi

Pravafen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Combined hyperlipidemia1 trial

References

Drug Info

Quick Facts

Related News